European Psychiatry
June 1, 2026
A. Kuzma-Hunt, Z. Hamadeh, V. Tsang
Introduction Ketamine-assisted therapy shows rapid benefit in treatment-resistant depression, anxiety, and PTSD (Walsh et al. BJPsych Open 2022;8:e19). The Roots to Thrive Ketamine assisted Therapy (RTT-KaT) program is a unique 12-week program that combines 12 Community of Practice (group therapy) sessions and three ketamine medicine sessions (Tsang et al. Ther Adv Psychopharmacol...
European Psychiatry
June 1, 2026
S. Wong, V. Tsang, B. Tao et al.
Introduction Positive feedback from a mental health treatment program that uses treatment adjuncts inspired researchers to assess the potential role of the Apollo Neuro device in mental health outcomes. Objectives To assess the impact of the Apollo Neuro device on anxiety levels in a ketamine-assisted therapy treatment program, comparing those using the device with those not using the device....
European Psychiatry
April 1, 2024
Shannon Dames, Crosbie Watler, P. Kryskow et al.
1 citation
Introduction This review explores the benefits of incorporating personal experience(s) with non-ordinary states of consciousness as a core component of Psychedelic-Assisted Therapy (PaT) training.The program incorporates an optional experiential training component. We collaborate with professionals affiliated with a Canadian non-profit organization specializing in PaT experiential training. As...
European Psychiatry
April 1, 2024
V. Tsang
IntroductionThe study aimed to evaluate the effectiveness of a device called “Apollo” in reducing anxiety, as compared to a control group. Participants were divided into two groups: the intervention group (receiving the “Apollo” device) and the control group (receiving no intervention).ObjectivesThe primary outcome measure was the change in Generalized Anxiety Disorder 7-item (GAD-7) scores,...
European Psychiatry
April 1, 2024
V. Tsang
Introduction While much is known about psilocybin-assisted therapy for individuals, little is known about the experience of participants in a group psilocybin therapy model. Objectives In an attempt to bridge this gap in the literature, a program development and quality improvement effort was launched. Methods Thirty-one psychedelic-assisted therapy (PaT) sessions were provided for 25...
European Psychiatry
April 1, 2024
V. Tsang
IntroductionDepression continues to present significant economic burdens to the Canadian healthcare system. Novel therapies, including those that incorporate psychoactive substances such as ketamine, present an opportunity to evaluate both clinical and economic effectiveness against current standards of care, which may be repeatedly proving ineffective in treating depression for some...
European Psychiatry
April 1, 2024
K. Sattler, T. Walia, V. Tsang
Introduction Currently, Ketamine is the only safe, effective, and widely used psychedelic-like medicine in Canada. It has demonstrated notably efficacy in providing relief to those experiencing treatment resistant mental health conditions. Pairing Ketamine treatment with psychotherapy, known as Ketamine Assisted Therapy (KAT), has been shown to yield more enduring outcomes. Work by Greenway et...
Journal of Psychoactive Drugs
September 1, 2023
V. Tsang, Dragos C Razagan, P. Kryskow et al.
10 citations
ABSTRACT The prevalence of depression, anxiety, and post-traumatic stress disorder (PTSD) has increased among healthcare providers, while the effectiveness of conventional treatments remains limited. Ketamine-assisted therapy offers a promising alternative; however, few have integrated ketamine with a group-based therapeutic modality. We report a retrospective, secondary analysis of a 12-week...